Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion
PositiveHealth

Roche's recent decision to acquire 89bio for up to $3.5 billion is a significant move aimed at enhancing its drug pipeline. This acquisition focuses on an experimental treatment for fatty liver disease, a condition increasingly associated with obesity. By investing in this promising therapy, Roche not only expands its portfolio but also addresses a growing health concern, potentially improving outcomes for many patients.
— Curated by the World Pulse Now AI Editorial System